Podcasts about advances

Nicole Bhave, Ashwini Kerkar, and Ahmed Kamal Siddiqi discuss what inspired this study, differences in mortality trends among age groups, and the most important takeaways from the paper.

Welcome to the latest Midlife Minute. This episode unpacks ongoing research on Lp(a), explores how women's lipids change during the perimenopause-to-menopause transition, and clarifies what we can do about it. Stay tuned for more! IN THIS EPISODE, YOU WILL LEARN: How total cholesterol, LDL, and ApoB tend to rise most steeply around the final menstrual period, rather than increasing gradually with chronological aging Why women should have their Lp(a) checked both before and after menopause How oral and transdermal estradiol can affect LDL, HDL, triglycerides, and Lp(a) differently Why I recommend including ApoB when checking your lipids during the perimenopause window How your lifestyle can reduce your cardiovascular risk, even when your Lp(a) is elevated Why omega-3 fatty acids and commonly used lipid medications do not lower Lp(a) Why supplements are not replacements for statins in genuinely high-risk patients  I review the various PCSK9 inhibitors currently available, how they are administered, and their effects  How a CAC, a CT angiogram, and an AI-assisted CT angiogram can help women and their providers determine how aggressive their approach should be when Lp(a) is elevated Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com  Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line References: 1. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association.Circulation. 2020. El Khoudary SR, Aggarwal B, Beckie TM, et al.Guideline 2. Menopause: A Cardiometabolic Transition. The Lancet. Diabetes & Endocrinology. 2022. Nappi RE, Chedraui P, Lambrinoudaki I, Simoncini T.Review 3. Dyslipidemia Across the Menopause Transition: Mechanisms, Trajectories, and Opportunities for Cardiovascular Prevention. Maturitas. 2026. Castaneda R, Tatit CP, Hurtado Andrade MD, Faubion SS, Shufelt CL.RecentReview 4. Lipoprotein(a) and Women's Cardiovascular Health: A Review. JACC. Advances. 2026. Michos ED, Saucier S, Mehran R, Koschinsky ML. 5. Lipid Metabolism in Women: A Review. Atherosclerosis. 2025. van Oortmerssen JAE, Mulder JWCM, Kavousi M, Roeters van Lennep JE.Review 6. Are Changes in Cardiovascular Disease Risk Factors in Midlife Women Due to Chronological Aging or to the Menopausal Transition?. Journal of the American College of Cardiology. 2009. Matthews KA, Crawford SL, Chae CU, et al.Observational 7. Trajectories of Lipids Around the Menopause Transition in Chinese Women: Results of the Kailuan Cohort Study. Fertility and Sterility. 2023. Dai Q, Wu S, Cao Z, et al. 8. Lipid Management in Patients With Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism. 2020. Newman CB, Blaha MJ, Boord JB, et al.Guideline 9. The Effects of Menopause Hormone Therapy on Lipid Profile in Postmenopausal Women: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 2022. Nie G, Yang X, Wang Y, et al.SR 10. Perspectives on Dyslipidemia and Coronary Heart Disease in Women. Journal of the American College of Cardiology. 2005. Bittner V.Review 11. Dyslipidemia in Midlife Women: Approach and Considerations During the Menopausal Transition. Maturitas. 2022. Torosyan N, Visrodia P, Torbati T, Minissian MB, Shufelt CL.Review 12. Effects of gender, age and menopausal status on serum apolipoprotein concentrations.13.Lipoprotein(a).The Journal of the American Medical Association. 2025. Mora S, Kronenberg     14. Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications. Diabetes, Obesity & Metabolism. 2025. Razavi AC, Bhatia HS, Blumenthal RS, Shapiro MD, Mehta A.RecentReview 15. Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar. Journal of the American College of Cardiology. 2021. Cicero AFG, Fogacci F, Zambon A.Review 16. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs. 2023. Blais JE, Huang X, Zhao JV.SR 17. Non-Genetic Influences on Lipoprotein(a) Concentrations. Atherosclerosis. 2022. Enkhmaa B, Berglund L.Review 18. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. Journal of the American College of Cardiology. 2018. Tsimikas S, Fazio S, Ferdinand KC, et al.Review 19. Consumption of a defined, plant‐based diet reduces lipoprotein(a), inflammation, and other atherogenic lipoproteins and particles within 4 weeks. Clinical Cardiology. 2018. Najjar RS, Moore CE, Montgomery BD. 20. Lipoprotein(a): Current Evidence for a Physiologic Role and the Effects of Nutraceutical Strategies. Clinical Therapeutics. 2019. Santos HO, Kones R, Rumana U, et al.Review 21. Effect of Lipid-Lowering Therapies on Lipoprotein(a) Levels: A Comprehensive Meta-Analysis of Randomized Controlled Trials. Atherosclerosis. 2025. Xie S, Galimberti F, Olmastroni E, et al.Recent 22. Effect of Omega-3 Fatty Acid Supplementation on the Postprandial Metabolism of Apolipoprotein(a) in Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis. 2023. Ying Q, Croyal M, Chan DC, et al.RCT 23.Lipoprotein(a) and Cardiovascular Disease. Lancet. 2024. Nordestgaard BG, Langsted A.Review 24. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022. Reyes-Soffer G, Ginsberg HN, Berglund L, et al.Guideline 25.Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3.Journal of the American College of Cardiology. 2023. Malick WA, Goonewardena SN, Koenig W, Rosenson RS.Review 26.2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American Collegeof Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026. Writing Committee Members, Blumenthal RS, Morris PB, et al.Guideline 27. Noninvasive Coronary Atherosclerotic Plaque Imaging. JACC. Cardiovascular Imaging. 2023. Kwiecinski J, Tzolos E, Williams MC, et al.Review 28. Computed Tomography Angiography Versus Agatston Score for Diagnosis of Coronary Artery Disease in Patients With Stable Chest Pain: Individual Patient Data Meta-Analysis of the International COME-CCT Consortium. European Radiology. 2022. Wieske V, Walther M, Dubourg B, et al.SR 29. Association of Coronary Artery Calcium Score With Qualitatively and Quantitatively Assessed Adverse Plaque on Coronary CT Angiography in the SCOT-HEART Trial. European Heart Journal. Cardiovascular Imaging. 2022. Osborne-Grinter M, Kwiecinski J, Doris M, et al.Clinical Trial 30. AI-Guided Quantitative Plaque Staging Predicts Long-Term Cardiovascular Outcomes in Patients at Risk for Atherosclerotic CVD. JACC. Cardiovascular Imaging. 2024. Nurmohamed NS, Bom MJ, Jukema RA, et al.Observational 31. The Lancet Commission on Rethinking Coronary Artery Disease: Moving From Ischemia to Atheroma. Lancet. 2025. Zaman S, Wasfy JH, Kapil V, et al.Review 32. Efficacy and safety of novel lipoprotein(a)‐targeted therapies: A systematic review and meta‐analysis of randomized controlled trials. Diabetes, Obesity & Metabolism. 2026. Santana AUL, Yusufzai MO, Freitas APS, et al. Recent Opinion

In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Joshua Brody, MD, the director of the Lymphoma Immunotherapy Program at the Mount Sinai Tisch Cancer Center and a faculty member of the Icahn Genomics Institute in New York, New York.Their discussion centered on the rapidly evolving treatment landscape for B-cell non-Hodgkin lymphomas, highlighting a wave of recent advances across frontline and relapsed diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) management. Drs Park and Brody framed this current era as one of unusually fast progress after decades of failed attempts to improve upon R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone).A major focus was the phase 3 frontMIND trial (NCT04824092), which added tafasitamab-cxix (Monjuvi) and lenalidomide (Revlimid) to R-CHOP in patients with frontline DLBCL. Dr Brody discussed the significant progression-free survival benefit with the experimental combination that extended across patient subgroups rather than being confined to patients with activated B-cell–like or non–germinal center disease, with only a modest increase in the rate of high-grade febrile neutropenia. He contextualized this against earlier trials in the DLBCL space.The discussion then turned to relapsed disease, where Dr Brody described the benefits of CAR T-cell therapy over stem cell transplant and reviewed bispecific antibody/chemotherapy combinations, including glofitamab-gxbm (Columvi) and epcoritamab-bysp (Epkinly) plus gemcitabine and oxaliplatin. He also emphasized the importance of clinical trials.Drs Park and Brody also explored the evolving MCL treatment paradigm, highlighting glofitamab's complete remission rate and the FDA approval of the BCL-2 inhibitor sonrotoclax (Beqalzi), alongside strategies to mitigate cytokine release syndrome and tumor lysis syndrome. The conversation concluded with a look at emerging therapies, including CD19-directed bispecific antibodies and in vivo CAR T-cell therapy delivered via viral and mRNA lipid nanoparticle vectors.

The Central Statistical Office is working to modernize the collection, analysis and dissemination of statistical information in Saint Lucia. The initiative will strengthen the country's statistical system, improve data-sharing and information technology capacity and prepare the office to make use of emerging technologies, including artificial intelligence.

Harena Rare Earths Executive Chairman Ivan Murphy joined Steve Darling from Proactive to discuss a major financing milestone for the company's flagship rare earths project in Madagascar, announcing that Harena has secured a US$5 million project funding facility from the U.S. International Development Finance Corporation (DFC). Murphy described the funding as the first step in what could become a broader strategic financing relationship with the DFC and other organizations connected to the U.S. government's critical minerals initiative. He noted that additional funding opportunities may become available as the project progresses through key development milestones and moves closer to commercial production. The funding underscores growing international interest in securing diversified sources of critical minerals outside China, particularly rare earth elements that are essential for electric vehicles, renewable energy technologies, advanced electronics and defense applications. Murphy highlighted that Harena's Madagascar asset is considered one of the largest proven ionic clay rare earth deposits outside China. Unlike many traditional hard-rock rare earth projects, ionic clay deposits offer significant operational advantages because they do not require extensive blasting, crushing or complex mineral processing in the early stages of development. As a result, Harena believes it can move from development to production more rapidly and at a potentially lower capital cost than many competing rare earth projects. The company is currently targeting initial production within approximately 20 to 24 months. A key component of the DFC partnership involves co-funding the construction of an onsite pilot plant and laboratory in Madagascar. Murphy explained that these facilities will allow the company to demonstrate, under real operating conditions, the same concentration and extraction processes that have already been successfully validated through independent laboratory testing. The pilot plant is expected to serve as a critical bridge between laboratory-scale validation and full-scale commercial production. Successful operation of the pilot facility would provide important technical data, support future financing discussions and help de-risk the project for potential strategic partners and investors. Looking ahead, Murphy identified completion of the pilot plant and laboratory as the company's most important objectives over the next two quarters. He said these milestones will play a central role in advancing project financing discussions and demonstrating the commercial viability of the deposit. Murphy also noted growing interest from potential offtake partners, which he believes has been strengthened by the project's connection to the U.S. government's critical minerals strategy. As global manufacturers seek secure and diversified rare earth supply chains, Harena is seeing increased inbound inquiries regarding future supply agreements. #harenaraerearths #otcqb #crmnf #lse #hree #RareEarths #CriticalMinerals #DFC #USDevelopmentFinance #MadagascarMining #RareEarthMining #EnergyTransition #EVSupplyChain #StrategicMetals #MiningNews #CleanEnergy #ResourceInvesting #ProactiveInvestors #SteveDarling

Honey Badger Silver CEO Chad Williams joined Steve Darling from Proactive to share news the company is taking significant steps toward unlocking value from two of its key northern Canadian assets, advancing plans to restart the historic PC Silver Mine in the Northwest Territories while expanding exploration efforts at its Nanisivik Project on Baffin Island, Nunavut. Williams explained that the PC Silver Mine is a rare asset because it already contains an extensive processing facility that was substantially completed in 1982 but never entered commercial operation. The facility has remained largely intact and well preserved for decades after the project was mothballed when silver prices declined. According to Williams, replacing the existing infrastructure today would likely cost at least $300 million and require several years to construct. As a result, understanding which components of the facility can be efficiently reused is expected to play a critical role in determining both the economics and timeline of a potential restart. Tusk Automation has begun an on-site assessment of the facilities, with fieldwork expected to be completed by the end of September and a final report anticipated by late November. While the study's findings will not be available in time to be incorporated into the company's upcoming Preliminary Economic Assessment (PEA), Honey Badger expects the work to provide engineering-level information suitable for inclusion in a future feasibility study. The company's broader objective is to accelerate the restart of the PC Silver Mine by leveraging the substantial infrastructure already in place and capitalizing on the decades of development work previously completed at the site. In addition to advancing the PC project, Honey Badger has completed its 2026 field exploration program at the Nanisivik Project, a historic mining district located on Baffin Island in Nunavut. The program builds on encouraging exploration results generated in 2025 and focuses on two emerging opportunities identified by the company. The first is an extensive massive-pyrite system that management believes may host additional valuable mineralization. The second is the potential for silver, zinc, lead and critical mineral enrichment located outside the historically mined areas. The 2026 campaign was specifically designed to improve the company's understanding of these targets using modern geological and analytical techniques. Field crews collected numerous samples that have been transported under strict chain-of-custody procedures and submitted to an independent accredited laboratory for comprehensive multi-element geochemical analysis. #proactiveinvestors #honeybadgersilver #tsxv #tuf #otcqb #hbeif #pcsilvermine #nanisivikproject #SilverMining #CriticalMinerals #NorthwestTerritories #Nunavut #Nanisivik #PCSilverMine #Mining #MineralExploration #Silver #Germanium #Zinc #Lead #ResourceSector #MiningStocks #CanadianMining #PreciousMetals #Infrastructure #Investing #ProactiveInvestors

The following article of the Policy & Economy industry is: 'Sheinbaum's Environmental Reform: Key Advances, Regulatory Risks' by Gabriel Quadri, Asesor, SIGEA. 

Work on the long-awaited Mon Repos Cemetery project is progressing, with the latest phase focused on concreting roads to improve access to the facility. Parliamentary Representative for Micoud North, Hon. Jeremiah Norbert, says the project is advancing in phases, with washroom facilities expected to be installed in the coming weeks.

The Central Statistical Office is moving forward with plans to modernize the way official statistics are collected, analyzed and shared in Saint Lucia. Government agencies and key stakeholders met recently to help shape a stronger, more responsive National Statistical System through a series of consultations supported by the World Bank-funded OECS Data for Decision Making Project.

Renforth Resources CEO Nicole Brewster joined Steve Darling from Proactive to provide an update on ongoing exploration and resource development activities at the company's Parbec Gold Deposit in Quebec, highlighting progress on drilling, surface sampling and an internal mineral resource estimate update. Brewster explained that Renforth has completed logging and sampling of drill core from two undercut drill holes completed in August 2026, marking the first drilling conducted on the Parbec Gold Deposit since 2022. The company has also carried out additional stripping and washing programs aimed at better defining previously identified gold-bearing surface channels located within the current open-pit footprint. The work forms part of a broader effort to refine the geological understanding of the deposit and support an updated geological model and resource estimate. Renforth is currently awaiting assay results from several recently completed channel samples, including CHNL-PAR-26-59, CHNL-PAR-26-60, CHNL-PAR-26-61 and CHNL-PAR-26-62, as well as assays from newly collected drill core samples and additional channel extensions and infill sampling. The company expects the results to provide valuable data for its ongoing modelling work. Brewster noted that drill holes PAR-26-149 and PAR-26-150 have now been fully logged by the geological team. During the logging process, geologists observed several encouraging features, including four fine flecks of visible gold within hole PAR-26-149. While visible gold is often considered a positive indicator, Brewster emphasized that such observations are uncommon at Parbec and should not be interpreted as a direct indication of grade due to the nature of gold distribution and assay methodologies. All selected drill core samples have been bagged, tagged and submitted for photon assay analysis, with results expected once laboratory processing is complete. In parallel with exploration activities, Renforth continues to advance an update to the Parbec geological model and mineral resource estimate. The company recently completed a Qualified Person site visit, including witness sampling, to support the ongoing technical review process. While the current resource update is being conducted internally, Brewster said the completion of the QP review and witness sampling provides the necessary groundwork should the company decide to publicly disclose the updated model and resource estimate in the future. Brewster also outlined early-stage process research at Victoria, noting the company has confirmed it can sort material to reduce waste and improve grade, process conventionally using grind and flotation, and is exploring newer technology to produce battery chemistry or precipitate metals directly. She described working with scientists on this approach, framing the project as being built from the ground up. #proacticeinvestors #renforthresources #cse #rfr otc #rfhrf #ParbecGold #GoldExploration #QuebecMining #GoldDeposit #MiningNews #ResourceUpdate #Abitibi #JuniorMining #GoldStocks #MineralResources #Exploration #VisibleGold #ProactiveInvestors #SteveDarling

The Houthis now control the vital Red Sea waterway including the key shipping lane through the Bab al-Mandab Strait. We hear from maritime and security experts.    As oil prices hit an unprecedented six dollars per barrel in the U.S., we go to South Dakota and Massachusetts to speak to American business owners about the impact of higher prices and lower wages.    And on the twenty fifth anniversary of 9/11,  the Speaker of the New York City Council tells us about how her city fought back, but also about the environmental consequences of the attack.   (Image Credit: EPA/Shutterstock)

This episode is sponsored by Estrotect and features Dr. George Perry from Texas A&M AgriLife, who discusses how estrus intensity influences reproductive performance in beef cattle and how producers can use that information to improve breeding decisions. While many producers think of estrus as a simple yes-or-no event, the discussion highlights that the intensity of estrus, measured by mounting activity or other indicators, can provide valuable insight into fertility. Calves and cows that exhibit stronger estrus prior to fixed-time artificial insemination consistently achieve higher conception rates than those showing weak or no signs of estrus. The conversation explains that estrus remains important even in synchronization and fixed-time AI programs, where breeding occurs on a set schedule. Research has shown that cattle displaying estrus before insemination can have conception rates more than 20 percentage points higher than those that do not. This information can help producers make more strategic decisions about which animals receive sexed semen or higher-value genetics. The group also emphasizes that management factors such as nutrition, body condition score, postpartum interval in cows, and puberty status in heifers often have a greater influence on estrus expression than genetics alone. Advances in estrus detection technology, including activity monitors and improved heat-detection aids, now provide producers with more detailed information than traditional visual observation methods. Ultimately, the discussion concludes that estrus intensity is not merely a biological curiosity but a valuable management tool. By combining sound nutrition, synchronization protocols, and improved estrus detection, producers can make better breeding decisions that improve conception rates, calf performance, and the long-term productivity of the herd.

Welcome to the latest Midlife Minute. Today, I'm answering listeners' questions about cardiovascular risk, focusing on Lp(a), LDL, statins, and the changes women experience after menopause. Stay tuned for more! IN THIS EPISODE, YOU WILL LEARN: Why women should have their Lp(a) checked both before and after menopause How Lp(a) works as a risk enhancer, and how cardiovascular risk becomes more significant when elevated Lp(a) occurs alongside high LDL Why family history is particularly helpful for women with a 10-year calculated cardiovascular risk that looks reassuringly low I review the current guidelines for primary prevention Why, even though research has shown reductions in major cardiac events with GLP-1s, GLP-1s do not replace statins for lowering LDL  What a CAC score can reveal about coronary artery calcification, and what it cannot detect How AI-assisted CT angiography (such as Clearly) can map, quantify, and characterize plaque throughout the coronary branches Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com  Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line References: 1.  ​Lipoprotein(a) and Women's Cardiovascular Health: A Review. JACC. Advances. 2026. Michos ED, Saucier S, Mehran R, Koschinsky ML.Recent 2.  ​Sex Differences of Lipoprotein(a) Levels and Associated Risk of Morbidity and Mortality by Age: The Copenhagen General Population Study. Atherosclerosis. 2022. Simony SB, Mortensen MB, Langsted A, et al. 3. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2022. Stone NJ, Smith SC, Orringer CE, et al.Review 4. Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a). JAMA Cardiology. 2026. Nordestgaard AT, Chasman DI, Moorthy V, et al.RecentObservational 5.  ​Lipoprotein(a).The Journal of the American Medical Association. 2025. Mora S, Kronenberg  6. Clinical Practice Guideline on Lipid Management for Cardiovascular Disease Risk Reduction. Department of Veterans Affairs (2026). 2026. Paul Heidenreich, Lance Spacek, Neil Gregor, et al. Guideline 7. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. Journal of the American College of Cardiology. 2020. Mehta A, Virani SS, Ayers CR, et al.Observational 8. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2010. Greenland P, Alpert JS, Beller GA, et al.Guideline 9. Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women. The Journal of the American Medical Association. 2016. Kavousi M, Desai CS, Ayers C, et al.SR 10. ​Coronary Artery Calcium Scores and Risk for Cardiovascular Events in Women Classified as “Low Risk” Based on Framingham Risk Score: The Multi-Ethnic Study of Atherosclerosis (MESA). Archives of Internal Medicine. 2007. Lakoski SG, Greenland P, Wong ND, et al.Observational 11. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019. Arnett DK, Blumenthal RS, Albert MA, et al.Guideline 12. HOPE for Rational Statin Allocation for Primary Prevention: A Coronary Artery Calcium Picture Is Worth 1000 Words. Mayo Clinic Proceedings. 2020. Orringer CE, Maki KC.Review 13. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2020. Cho L, Davis M, Elgendy I, et al.Review 14. Health Maintenance in Postmenopausal Women. American Family Physician. 2025. Plesa M, Wong A, Katsaggelos E.Guideline 15.  ​Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes Care. 2024. Lingvay I, Deanfield J, Kahn SE, et al.RCT 16.  ​Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine. 2023. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.RCT 17. Long-Term Weight Loss Effects of Semaglutide in Obesity Without Diabetes in the SELECT Trial. Nature Medicine. 2024. Ryan DH, Lingvay I, Deanfield J, et al.RCT 18. Interventions for the Prevention and Management of Cardiometabolic Multiple Long-Term Conditions. Lancet. 2026. Valabhji J, Hope D, Sayed NE, et al.RecentReview 19. Glucagon‐Like Peptide‐1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta‐Analysis of Randomized‐Controlled Trials. Clinical Cardiology. 2024. Hosseinpour A, Sood A, Kamalpour J, et al.SR 20. ​FDA Orange Book. FDA Orange Book. 2026. 21. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026. American Diabetes Association Professional Practice Committee for Diabetes*.RecentGuideline 22. Premature Coronary Artery Disease in Women: Sex-Specific Risk Factors, Pathogenetic Mechanisms and Clinical Implications. Annals of Medicine. 2026. Li F, Hong D, Yang M, et al.RecentReview 23. Cardiovascular Disease Risk Factors in Women: The Impact of Race and Ethnicity: A Scientific Statement From the American Heart Association. Circulation. 2023. Mehta LS, Velarde GP, Lewey J, et al.Guideline 24. Preventing CVD in Women: Common Questions and Answers. American Family Physician. 2023. Westfall E, Viere AB, Genewick JE.Review 25. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020. El Khoudary SR, Aggarwal B, Beckie TM, et al.Guideline

September 9th: Jerry Westrom Sentenced (2022) Advances in technology have thawed long cold cases. On September 9th 2022 a man was sentenced for a decades old cold case. One he likely thought he got away with.  *Suggested by Perrie https://www.oxygen.com/crime-news/jerry-westrom-guilty-jeanne-childs-1993-cold-case-murder, https://www.washingtonpost.com/nation/2022/08/30/hotdog-napkin-minnesota-murder-jeanie-childs/, https://www.fox9.com/news/mpls-cold-case-murder-supreme-court-vacates-conviction-but-suspect-will-stay-in-prison, https://www.cbsnews.com/minnesota/news/us-supreme-court-jerry-westrom-denies-petition/, https://www.cbsnews.com/minnesota/news/jerry-westroms-appeal-in-jeanie-childs-murder-conviction-goes-before-minnesota-supreme-court-monday/, https://kstp.com/kstp-news/local-news/minnesota-supreme-court-justices-weigh-appeal-of-man-convicted-in-1993-cold-case/, https://www.investigationdiscovery.com/crimefeed/murder/man-convicted-of-1993-cold-case-murder-of-woman-stabbed-65-times-in-her-minnesota-apartment, https://www.cbsnews.com/minnesota/news/jerry-westrom-trial-begins-jeanie-ann-childs-murder-1993/, https://abc7chicago.com/cold-case-murder-solved-jerry-westrom/12216836/, https://www.theguardian.com/us-news/2019/feb/18/minneapolis-jeanie-childs-dna-napkin-cold-case, https://www.fox9.com/news/jerry-westrom-sentenced-to-life-in-prison-for-1993-murder Learn more about your ad choices. Visit megaphone.fm/adchoices

Guest: Mike OlbinskiFor most people, a thunderstorm is something you watch from a window. But for storm chasers, it's a front-row seat to some of nature's most spectacular displays—and few have captured those moments as beautifully as today's guest. On this episode of Weather Geeks, we're joined by storm chaser and filmmaker Mike Olbinski. Based in the Desert Southwest, Mike has spent years documenting everything from towering monsoon thunderstorms and dramatic haboobs to lightning-filled skies across the Great Plains, creating breathtaking imagery that has inspired weather enthusiasts around the world. We'll talk about what makes chasing storms in Arizona so unique, some of the unforgettable moments he's experienced on the road, and how the art of storm storytelling has evolved alongside advances in cameras, social media, and live streaming.Chapters00:00 Introduction to Mike Olbinski and his work13:38 Break 113:39 How technology has changed storm chasing24:38 Break 224:40 Advances in weather models and forecasting26:53 Mobile connectivity and Starlink for storm chasing28:22 Apps and tools for real-time weather data28:45 Use of drones in storm photography29:45 Carving out a niche in storm photography30:22 Advice for aspiring storm chasers and photographers32:34 Platforms to follow Mike Olbinski33:24 Closing remarks and upcoming projectsResourcesStorm Photo Contests - https://stormphotocontest.com/Stormchaser Atlas App - https://stormchaseratlas.com/Weatherfront App - https://weatherfront.com/ Guest linksInstagram - https://www.instagram.com/mikeolbinski/YouTube - https://www.youtube.com/user/mikeolbinskiSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this solo episode of the Explaining History Podcast, we examine the recent electoral victory of the Alternative for Germany (AFD) in the state of Saxony-Anhalt – and what it tells us about the global resurgence of the far right.The AFD's crushing victory has alarmed commentators around the world. An openly fascist party emerging in Germany has a special and terrifying significance. But as veteran left intellectual Tariq Ali argues in a powerful Substack essay, this is not an isolated phenomenon. It is part of a global trend – and it is a direct consequence of the failures of neoliberalism and the "extreme centre."Ali writes that the election results "are not a huge surprise." The so-called firewall created by the extreme centre parties of the German elite has only aided the AFD's growth. The Christian Democratic Union, which won 37% in 2021, is now down to 18.5%. Meanwhile, Die Linke has won more votes than the Social Democratic Party, and the Sahra Wagenknecht Party has crossed the 5% threshold.The problem, Ali argues, is that the political and economic elites insist "that no reforms are possible and the current form of capitalism is fixed indefinitely." Telling people that an economic system that erodes their living standards year after year is the only option has created a vacuum that the far right is only too happy to fill.We also explore the historical context: the incomplete reckoning with Europe's fascist past, the failure of post-war denazification, and the erosion of the social democratic contract that once made Germany and other European countries resistant to extremism.Topics covered:The AFD's victory in Saxony-AnhaltTariq Ali's analysis of the rise of the far rightThe failure of the "extreme centre"Neoliberalism and the erosion of living standardsThe collapse of the post-war social democratic contractEurope's incomplete reckoning with fascismThe global nature of far-right resurgenceIf you enjoy the podcast, please consider supporting us – we are migrating from Patreon to Substack. Details in the show notes.Explaining History helps you understand the 20th Century through critical conversations and expert interviews. We connect the past to the present. If you enjoy the show, please subscribe and share.▸ Support the Show & Get Exclusive ContentBecome a Patron: patreon.com/explaininghistory▸ Join the Community & Continue the ConversationFacebook Group: facebook.com/groups/ExplainingHistoryPodcastSubstack: theexplaininghistorypodcast.substack.com▸ Read Articles & Go DeeperWebsite: explaininghistory.org Hosted on Acast. See acast.com/privacy for more information.

In the third and final part of our interview with Dr. Johannes Michaelian of the University of Sydney's Brain and Mind Centre, we explore the future of dementia research. The discussion highlights promising developments in clinical trials, emerging treatment strategies, and the importance of earlier diagnosis. Dr. Michaelian also emphasises the need for greater inclusivity in clinical research and explains how broader participation can improve outcomes for diverse communities.

Dormant omics data are a goldmine for CMC innovation waiting to be unlocked. But legacy structures, poor annotation, and spreadsheet chaos hold most biotech teams back from the real breakthroughs.Nathan Lewis, GRA Eminent Scholar at the Center for Molecular Medicine, Complex Carbohydrate Research Center, and Department of Biochemistry and Molecular Biology at the University of Georgia, has a clear message: actionable data is now within reach thanks to hybrid modeling, advanced study design, and AI as a true scientific collaborator.Topics discussed:Rethinking the dogma: controlling protein glycosylation quality from the inside out, not just by bioprocess conditions (03:00)Nathan Lewis's journey into science and bioprocessing, from unexpected college choices to pivotal advances in CHO cell engineering (05:12)The evolution of omics in bioprocessing: why actionable insights, not just big datasets, should be the goal (10:49)Strategic advice for structuring, annotating, and making old and new datasets ready for AI and LLM analysis (17:34)The balance between mechanistic and machine learning models—when each makes sense, and why hybrid modeling is gaining ground (22:20)The current and future role of digital twins in process development and why foundation models and data consortia matter for scalability (26:24)Smart insight: The real revolution isn't in making new data, but in unlocking the value of what already exists. Advances in AI, hybrid modeling, and collaborative standards promise to turn decades-old data into a catalyst for innovation—enabling faster, smarter, and more reliable bioprocess development.If this got you thinking about the data already sitting in your freezer — and what it would take to actually use it — start here. These four dig into AI-ready data, actionable omics, hybrid-model digital twins, and the cell-engineering biology underneath it all.Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David HardyEpisodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist GernaeyEpisodes 169 - 170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo JainEpisodes 77 - 78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro TorresIf you'd rather follow the glycosylation thread, check Episodes 69 - 70: Glycoanalytics Explained with Róisín O'FlahertyConnect with Nathan Lewis:Website: www.lewislab.uga.edu LinkedIn: www.linkedin.com/in/nathanelewisFree 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it hereSupport the show

Contributor: Alec Coston, MD Educational Pearls: Benign Paroxysmal Positional Vertigo (BPPV) Common inner ear condition that can cause dizziness Diagnosis of BPPV can help to avoid admissions and extra imaging Three categories: positional, horizontal, and anterior Positional is the most common  Dizziness is not a positive indicator, a torsional nystagmus must be induced Dix's hallpike maneuver is done to diagnose and an epley maneuver is then used for treatment  Horizontal  Usually determined to be the case if the vertigo seems positional and the dix hallpike does not work. A supine roll test would then be done to help diagnose. Instead of a rotational nystagmus, a unilateral horizontal nystagmus is expected. The two patterns are termed geotropic and apogeotropic. Geotropic means the fast phase beats toward the ground, and is treated by a barbeque roll maneuver. Apogeotropic means the fast phase beats toward the ceiling, and is treated by Gufoni maneuver. Anterior is more rare Most cases require neuro consults Determined by attempting to induce a down-beating nystagmus, which is a higher risk nystagmus. Treatment is tilting their head back up in a similar way Inducing the nystagmus is not sided and is more central   References You, P., Instrum, R. and Parnes, L. (2019), Benign paroxysmal positional vertigo. Laryngoscope Investigative Otolaryngology, 4: 116-123. https://doi.org/10.1002/lio2.230  Ling X, Zhao D-H, Shen B, Si L-H, Li K-Z, Hong Y, Li Z-Y and Yang X (2020) Clinical Characteristics of Patients With Benign Paroxysmal Positional Vertigo Diagnosed Based on the Diagnostic Criteria of the Bárány Society. Front. Neurol. 11:602. doi: 10.3389/fneur.2020.00602 Rah YC. Advances in Benign Paroxysmal Positional Vertigo: Updated Insights on Diagnostic Pitfalls and Management. J Audiol Otol. 2026 Jan;30(1):1-12. doi: 10.7874/jao.2025.00717.   Summarized by Aaryn David | Edited by Aaryn David & Ahmed Abdel-Hafiz, NREMT-P   Donate: https://emergencymedicalminute.org/donate/   Join our mailing list: http://eepurl.com/c9ouHf

Bibliography**Advertising, Branding, and Consumer Identity**Aaker, *Managing Brand Equity* (1991); Bernays, *Biography of an Idea* (1965); Bernays, *Propaganda* (1928); Ewen, *Captains of Consciousness* (1976); Keller, *Strategic Brand Management* (1998); McCracken, “Culture and Consumption,” *JCR* 13 (1986): 71–84; Schudson, *Advertising, the Uneasy Persuasion* (1984); Tye, *The Father of Spin* (1998); Zajonc, “Attitudinal Effects of Mere Exposure,” *JPSP* 9 (1968): 1–27.**Propaganda, Language, and Ideology**Ellul, *Propaganda* (1965); Klemperer, *The Language of the Third Reich* (2000); Lasswell, *Propaganda Technique in the World War* (1927); Lifton, *Thought Reform and the Psychology of Totalism* (1989; orig. 1961); Stanley, *How Propaganda Works* (2015).**Framing, Agenda Setting, and Public Attention**Entman, “Framing,” *Journal of Communication* 43 (1993): 51–58; Iyengar, *Is Anyone Responsible?* (1991); Lippmann, *Public Opinion* (1922); McCombs, *Setting the Agenda* (2014); McCombs and Shaw, “The Agenda-Setting Function of Mass Media,” *POQ* 36 (1972): 176–87; Noelle-Neumann, *The Spiral of Silence* (1993).**Dehumanization and Moral Disengagement**Bandura, “Moral Disengagement in the Perpetration of Inhumanities,” *PSPR* 3 (1999): 193–209; Haslam, “Dehumanization,” *PSPR* 10 (2006): 252–64; Haslam and Loughnan, “Dehumanization and Infrahumanization,” *ARP* 65 (2014): 399–423; Kelman, “Violence Without Moral Restraint,” *JSI* 29 (1973): 25–61.**Repetition, Misinformation, and Online Diffusion**Bail, *Breaking the Social Media Prism* (2021); Berger and Milkman, “What Makes Online Content Viral?” *JMR* 49 (2012): 192–205; Brady et al., “Emotion Shapes the Diffusion of Moralized Content,” *PNAS* 114 (2017): 7313–18; Pennycook et al., “Prior Exposure Increases Perceived Accuracy of Fake News,” *JEP:G* 147 (2018): 1865–80; Pennycook et al., “Fighting COVID-19 Misinformation,” *Psychological Science* 31 (2020): 770–80; Vosoughi, Roy, and Aral, “The Spread of True and False News Online,” *Science* 359 (2018): 1146–51.**Availability, Consensus, and Social Silence**Kuran and Sunstein, “Availability Cascades and Risk Regulation,” *Stanford Law Review* 51 (1999): 683–768; Prentice and Miller, “Pluralistic Ignorance and Alcohol Use on Campus,” *JPSP* 64 (1993): 243–56; Sunstein, *On Rumors* (2009).**Liturgy, Civil Religion, and Collective Ritual**Bell, *Ritual Theory, Ritual Practice* (1992); Bellah, “Civil Religion in America,” *Daedalus* 96 (1967): 1–21; Durkheim, *The Elementary Forms of Religious Life* (1995; orig. 1912); Hobson et al., “The Psychology of Rituals,” *PSPR* 22 (2018): 260–84; Rappaport, *Ritual and Religion in the Making of Humanity* (1999); Whitehouse, *Modes of Religiosity* (2004); Xygalatas, *Ritual* (2022).**Crowd Psychology, Synchrony, and Collective Identity**Canetti, *Crowds and Power* (1962); Drury, “Social Identity Processes in Mass Emergency Behaviour,” *ERSP* 29 (2018): 38–81; Drury and Reicher, “Collective Action and Psychological Change,” *BJSP* 39 (2000): 579–604; Le Bon, *The Crowd* (1896); McNeill, *Keeping Together in Time* (1995); Reicher, “The St. Pauls' Riot,” *EJSP* 14 (1984): 1–21; Reicher, Spears, and Postmes, “A Social Identity Model of Deindividuation,” *ERSP* 6 (1995): 161–98; Stott and Reicher, “How Conflict Escalates,” *Sociology* 32 (1998): 353–77; Tajfel and Turner, “An Integrative Theory of Intergroup Conflict” (1979); Turner et al., *Rediscovering the Social Group* (1987); Vickhoff et al., “Music Structure Determines Heart Rate Variability,” *Frontiers in Psychology* 4 (2013): 334; Wiltermuth and Heath, “Synchrony and Cooperation,” *Psychological Science* 20 (2009): 1–5.**Prebunking, Inoculation, and Resistance**Compton, “Inoculation Theory” (2013); Linegar et al., “Prebunking Election Rumors” (preprint, 2024); McGuire, “Inducing Resistance to Persuasion,” *Advances in Experimental Social Psychology* 1 (1964): 191–229; Roozenbeek et al., “Psychological Inoculation Improves Resilience Against Misinformation,” *Science Advances* 8 (2022): eabo6254; Traberg, Roozenbeek, and van der Linden, “Psychological Inoculation Against Misinformation,” *Annals AAPSS* 700 (2022): 136–51.Also want to remind people about the website, if you're into reading we have tons of information by multiple contributors, and we got t-shirts up on the site if you're interested. Fun fact, the art is all based on the eyeball. 

Andy Roddick breaks down the results from Day 7 of the US Open 2026. Roddick reacts to the “match of the tournament so far” Iva Jovic defeats Alex Eala in 3 sets. He also talks about Taylor Fritz and Madison Keys exiting in the third round. All of this and more from the Cadillac IQ mobile studio! COMMENT BELOW: What was your favorite match of Day 7? FILL OUT YOUR REDRAW: https://served.bracket.tennis/ TAKE OUR SURVEY! https://survey.alchemer.com/s3/894283...

⁠

Credits: 0.75 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  Episode resource links:  Zhou H et al.  Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355.  eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884  Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041   Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257  Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698.  Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930.  Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.  Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.:  American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022.  Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485.  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234.  Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455  Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666  Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301.  Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015  Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024  Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575  Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1  Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Small cell lung cancer (SCLC) has historically lagged behind other cancers in treatment innovation — but that's changing fast. In this Hope With Answers episode, 8-year SCLC survivor and LCFA patient host Maida Mangiameli talks with Dr. Jacob Sands, Associate Chief of Thoracic Oncology at Dana-Farber Cancer Institute, about the surge of new SCLC clinical trials, why immunotherapy has changed long-term outcomes, and what newly diagnosed patients need to know about acting quickly. Learn more at LCFAmerica.org. Guests: Dr. Jacob Sands (Dana-Farber Cancer Institute) Maida Mangiameli (LCFA Patient Host, SCLC Survivor) Resources Show Notes - https://lcfamerica.org/wp-content/uploads/2026/08/HWA-Fall-2026-SCLC-Advances-Deeper-Dive-Show-Notes.pdf  Transcript - https://lcfamerica.org/wp-content/uploads/2026/08/HWA-Fall-2026-SCLC-Deeper-Dive-Transcript.pdf Watch Video - https://youtu.be/wxLk2OqKuB4  

Dominique Mamcarz, Director of Sustainability at Geopost, discusses Geopost's sustainability strategy and its recent Sustainability Report. Embedding sustainability in the Geopost business Geopost's sustainability programme A pragmatic approach to reducing Geopost's carbon footprint Measuring emissions reliably and customers' emissions reporting The role of Geopost's Carbon Calculator Breakdown of Geopost's carbon emissions Replacing diesel vehicles with electric vehicles Advances in electric vehicles and TCO Challenges in line haul, including biofuels and electrification Charging infrastructure and scheduling challenges Solar panels and making best use of Geopost facilities Producing and storing electricity at Geopost sites Future of sustainability at Geopost Preparedness for extreme weather events Low-emission, low-traffic, and green zones in city centres  

Credits: 0.75 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  Episode resource links:  Zhou H et al.  Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355.  eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884  Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041   Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257  Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698.  Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930.  Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.  Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.:  American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022.  Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485.  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234.  Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455  Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666  Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301.  Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015  Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024  Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575  Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1  Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

 How to read Publisher's Marketplace Deal Reports and other arcania of how traditional publishing finances work. Also my very cool appearances at Fan X Phoenix and people who do and don't (and why it isn't shocking at all). Preorder ~Among The ThornsIndie Booksellers! You can buy my indie books direct from me at discount!! Submit a Request for an order hereNew Releases ~Blades, Books, and the BanditLove, Lies, and Ley LinesMAGIC REBORNNever The RosesThe posture correcting sports bra I love almost more than life itself can be found hereThank you for listening! You all take care. Support the show

Pretty CFD flames are something we got used to, but they usually are a product of our design assumptions - the design fire. While they give us a lovely illusion of being "real" fires, predicting real compartment fire growth is a completely different game. We're joined by Dr. Stephen Welch (University of Edinburgh) to get honest about what “modeling fire spread” actually means, how quickly results can become believable but wrong, and why validation has to be the foundation of any serious CFD fire modeling workflow. We walk through the path his group has taken from traveling fires in large compartments to timber-lined compartment behavior, using FDS and detailed pyrolysis models. Along the way we talk about scaling up from cone and crib experiments, why wood sticks burn differently than flat timber, and why calibrated kinetics are often engineering tools rather than universal material truths. We also dig into the uncomfortable reality of scenario uncertainty: moisture, stick variability, crib deformation, and tiny geometric changes can meaningfully shift predictions. One of the most practical takeaways is how opening location and ventilation momentum reshape fire spread, sometimes in ways classic simplified models won't anticipate. We explore entrainment height, hot layer effects, soot and radiative fraction, and what it might take to credibly predict burnout and post-burner behavior in timber-lined compartments. If you care about structural fire design, traveling fire exposure, and the future of validated predictive modeling, this one is for you. After this one, you will have a lot of reading... Start with these:Liu, C., Dai, X., Ming, X.M. & Welch, S. (2026) Exploring fire dynamics of travelling fires in large open compartments with CFD, Fire Safety Journal 104663 (special issue IAFSS2026) doi:10.1016/j.firesaf.2026.104663Liu, C., Dai, X., Ming, X.M. & Welch, S. (2025) CFD predictions of fire spread over wood cribs in large open-plan compartments: new insights, Fire Safety Journal special issue 156: 104443 doi:10.1016/j.firesaf.2025.104443  Dai, X., Alam, N., Liu, C., Nadjai, A., Rush, D. & Welch, S. (2024) “Scaling-up” fire spread on wood cribs to predict a large-scale travelling fire test using CFD, Advances in Engineering Software 189: 103589 doi: 10.1016/j.advengsoft.2023.103589Dai, X., Gamba, A., Liu, C., Anderson, J., Charlier, M., Rush, D. & Welch, S. (2022) An engineering CFD model for fire spread on wood cribs for travelling fires, Advances in Engineering Software 173:103213 doi: 10.1016/j.advengsoft.2022.103213 And the cover image comes from the image in paper [2], Fig. 17. Stephens papers are full of beautiful images. Another reason to check them out.----The Fire Science Show is produced by the Fire Science Media in collaboration with OFR Consultants. Thank you to the podcast sponsor for their continuous support towards our mission.

Matt Martinez and Bradley Petek discuss how the study came about, what results were discovered, and what call to action this study brings.

Credits: 0.75 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  Episode resource links:  Zhou H et al.  Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355.  eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884  Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041   Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257  Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698.  Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930.  Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.  Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.:  American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022.  Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485.  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234.  Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455  Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666  Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301.  Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015  Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024  Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575  Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1  Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Links For The Occult Rejectshttps://linktr.ee/theoccultrejectsOccult Research Institutehttps://www.occultresearchinstitute.org/Substackhttps://substack.com/@theoccultrejects?r=7auau0&utm_campaign=profile&utm_medium=profile-pageCash Apphttps://cash.app/$theoccultrejectsVenmo@TheOccultRejectsBuy Me A Coffeebuymeacoffee.com/TheOccultRejectsPatreonhttps://www.patreon.com/TheOccultRejectsBibliographyCurses, Blessings, and Ritual HarmCannon, Walter B. “‘Voodoo' Death.” American Anthropologist 44, no. 2 (1942): 169–181.Faraone, Christopher A. Ancient Greek Love Magic. Cambridge, MA: Harvard University Press, 1999.Gager, John G., ed. Curse Tablets and Binding Spells from the Ancient World. New York: Oxford University Press, 1992.Graf, Fritz. Magic in the Ancient World. Translated by Franklin Philip. Cambridge, MA: Harvard University Press, 1997.Ogden, Daniel. Magic, Witchcraft, and Ghosts in the Greek and Roman Worlds: A Sourcebook. 2nd ed. New York: Oxford University Press, 2009.Stratton, Kimberly B., and Dayna S. Kalleres, eds. Daughters of Hecate: Women and Magic in the Ancient World. New York: Oxford University Press, 2014.Tambiah, Stanley Jeyaraja. “The Magical Power of Words.” Man 3, no. 2 (1968): 175–208.Placebo, Nocebo, and Medical CommunicationBarsky, Arthur J., Ralph Saintfort, Malcolm P. Rogers, and Jonathan F. Borus. “Nonspecific Medication Side Effects and the Nocebo Phenomenon.” JAMA 287, no. 5 (2002): 622–627.Benedetti, Fabrizio. Placebo Effects: Understanding the Mechanisms in Health and Disease. Oxford: Oxford University Press, 2009.Benedetti, Fabrizio, Marina Lanotte, Lorella Lopiano, and Luana Colloca. “When Words Are Painful: Unraveling the Mechanisms of the Nocebo Effect.” Neuroscience 147, no. 2 (2007): 260–271.Colloca, Luana, and Fabrizio Benedetti. “Nocebo Hyperalgesia: How Anxiety Is Turned into Pain.” Current Opinion in Anaesthesiology 20, no. 5 (2007): 435–439.Colloca, Luana, and Damien Finniss. “Nocebo Effects, Patient–Clinician Communication, and Therapeutic Outcomes.” JAMA 307, no. 6 (2012): 567–568.Colloca, Luana, and Franklin G. Miller. “The Nocebo Effect and Its Relevance for Clinical Practice.” Psychosomatic Medicine 73, no. 7 (2011): 598–603.Enck, Paul, Fabrizio Benedetti, and Manfred Schedlowski. “New Insights into the Placebo and Nocebo Responses.” Neuron 59, no. 2 (2008): 195–206.Häuser, Winfried, Ernil Hansen, and Paul Enck. “Nocebo Phenomena in Medicine: Their Relevance in Everyday Clinical Practice.” Deutsches Ärzteblatt International 109, no. 26 (2012): 459–465.Inner Speech and DevelopmentFernyhough, Charles. The Voices Within: The History and Science of How We Talk to Ourselves. New York: Basic Books, 2016.Vygotsky, Lev S. Thought and Language. Revised and expanded ed. Edited and translated by Alex Kozulin. Cambridge, MA: MIT Press, 1986.Winsler, Adam, Charles Fernyhough, and Ignacio Montero, eds. Private Speech, Executive Functioning, and the Development of Verbal Self-Regulation. Cambridge: Cambridge University Press, 2009.Rumination and Repetitive Negative ThinkingBrosschot, Jos F., Bart Verkuil, and Julian F. Thayer. “Conscious and Unconscious Perseverative Cognition: Is a Large Part of Prolonged Physiological Activity Due to Unconscious Stress?” Journal of Psychosomatic Research 69, no. 4 (2010): 407–416.Ehring, Thomas, and Edward R. Watkins. “Repetitive Negative Thinking as a Transdiagnostic Process.” International Journal of Cognitive Therapy 1, no. 3 (2008): 192–205.Nolen-Hoeksema, Susan. “Responses to Depression and Their Effects on the Duration of Depressive Episodes.” Journal of Abnormal Psychology 100, no. 4 (1991): 569–582.Nolen-Hoeksema, Susan, Blair E. Wisco, and Sonja Lyubomirsky. “Rethinking Rumination.” Perspectives on Psychological Science 3, no. 5 (2008): 400–424.Smith, Jeannette M., and Lauren B. Alloy. “A Roadmap to Rumination: A Review of the Definition, Assessment, and Conceptualization of This Multifaceted Construct.” Clinical Psychology Review 29, no. 2 (2009): 116–128.Treynor, Wendy, Richard Gonzalez, and Susan Nolen-Hoeksema. “Rumination Reconsidered: A Psychometric Analysis.” Cognitive Therapy and Research 27, no. 3 (2003): 247–259.Watkins, Edward R. “Constructive and Unconstructive Repetitive Thought.” Psychological Bulletin 134, no. 2 (2008): 163–206.Watkins, Edward R. Rumination-Focused Cognitive-Behavioral Therapy for Depression. New York: Guilford Press, 2016.Self-Talk and PerformanceHardy, James. “Speaking Clearly: A Critical Review of the Self-Talk Literature.” Psychology of Sport and Exercise 7, no. 1 (2006): 81–97.Hatzigeorgiadis, Antonis, Nikos Zourbanos, Evangelos Galanis, and Yiannis Theodorakis. “Self-Talk and Sports Performance: A Meta-Analysis.” Perspectives on Psychological Science 6, no. 4 (2011): 348–356.Theodorakis, Yiannis, Antonis Hatzigeorgiadis, and Nikos Zourbanos. “Cognition: Self-Talk and Performance.” In The Oxford Handbook of Sport and Performance Psychology, edited by Shane M. Murphy. New York: Oxford University Press, 2012.Affect Labeling, Emotion, and LanguageBarrett, Lisa Feldman. “Solving the Emotion Paradox: Categorization and the Experience of Emotion.” Personality and Social Psychology Review 10, no. 1 (2006): 20–46.Lieberman, Matthew D., Naomi I. Eisenberger, Molly J. Crockett, Sabrina M. Tom, Jennifer H. Pfeifer, and Baldwin M. Way. “Putting Feelings into Words: Affect Labeling Disrupts Amygdala Activity in Response to Affective Stimuli.” Psychological Science 18, no. 5 (2007): 421–428.Lindquist, Kristen A., Lisa Feldman Barrett, Eliza Bliss-Moreau, and James A. Russell. “Language and the Perception of Emotion.” Emotion 6, no. 1 (2006): 125–138.Torre, Jared B., and Matthew D. Lieberman. “Putting Feelings into Words: Affect Labeling as Implicit Emotion Regulation.” Emotion Review 10, no. 2 (2018): 116–124.Self-Distancing and Reflective ProcessingAyduk, Özlem, and Ethan Kross. “From a Distance: Implications of Spontaneous Self-Distancing for Adaptive Self-Reflection.” Journal of Personality and Social Psychology 98, no. 5 (2010): 809–829.Kross, Ethan, and Özlem Ayduk. “Making Meaning out of Negative Experiences by Self-Distancing.” Current Directions in Psychological Science 20, no. 3 (2011): 187–191.Kross, Ethan, Özlem Ayduk, and Walter Mischel. “When Asking ‘Why' Does Not Hurt: Distinguishing Rumination from Reflective Processing of Negative Emotions.” Psychological Science 16, no. 9 (2005): 709–715.Kross, Ethan, Emma Bruehlman-Senecal, Jiyoung Park, Aleah Burson, Adrienne Dougherty, Holly Shablack, Ryan Bremner, Jason Moser, and Özlem Ayduk. “Self-Talk as a Regulatory Mechanism: How You Do It Matters.” Journal of Personality and Social Psychology 106, no. 2 (2014): 304–324.Moser, Jason S., Adrienne Dougherty, Whitney I. Mattson, Benjamin Katz, Tim P. Moran, Darwin Guevarra, Hannah Shablack, et al. “Third-Person Self-Talk Facilitates Emotion Regulation Without Engaging Cognitive Control: Converging Evidence from ERP and fMRI.” Scientific Reports 7 (2017): 4519.Affirmation and Counter-IncantationCascio, Christopher N., Matthew B. O'Donnell, Francis J. Tinney Jr., Matthew D. Lieberman, Shelley E. Taylor, Victor J. Strecher, and Emily B. Falk. “Self-Affirmation Activates Brain Systems Associated with Self-Related Processing and Reward and Is Reinforced by Future Orientation.” Social Cognitive and Affective Neuroscience 11, no. 4 (2016): 621–629.Cohen, Geoffrey L., and David K. Sherman. “The Psychology of Change: Self-Affirmation and Social Psychological Intervention.” Annual Review of Psychology 65 (2014): 333–371.Wood, Joanne V., W. Q. Elaine Perunovic, and John W. Lee. “Positive Self-Statements: Power for Some, Peril for Others.” Psychological Science 20, no. 7 (2009): 860–866.Implementation Intentions and ActionGollwitzer, Peter M. “Implementation Intentions: Strong Effects of Simple Plans.” American Psychologist 54, no. 7 (1999): 493–503.Gollwitzer, Peter M., and Veronika Brandstätter. “Implementation Intentions and Effective Goal Pursuit.” Journal of Personality and Social Psychology 73, no. 1 (1997): 186–199.Gollwitzer, Peter M., and Paschal Sheeran. “Implementation Intentions and Goal Achievement: A Meta-Analysis of Effects and Processes.” Advances in Experimental Social Psychology 38 (2006): 69–119.Schweiger Gallo, Inge, Andreas Keil, Kathleen C. McCulloch, Brigitte Rockstroh, and Peter M. Gollwitzer. “Strategic Automation of Emotion Regulation.” Journal of Personality and Social Psychology 96, no. 1 (2009): 11–31.Ritual, Identity, and Psychological FormationBell, Catherine. Ritual Theory, Ritual Practice. New York: Oxford University Press, 1992.Hobson, Nicholas M., Juliana Schroeder, Jane L. Risen, Dimitris Xygalatas, and Michael Inzlicht. “The Psychology of Rituals: An Integrative Review and Process-Based Framework.” Personality and Social Psychology Review 22, no. 3 (2018): 260–284.Rappaport, Roy A. Ritual and Religion in the Making of Humanity. Cambridge: Cambridge University Press, 1999.Xygalatas, Dimitris. Ritual: How Seemingly Senseless Acts Make Life Worth Living. New York: Little, Brown Spark, 2022.Also want to remind people about the website, if you're into reading we have tons of information by multiple contributors, and we got t-shirts up on the site if you're interested. Fun fact, the art is all based on the eyeball. 

The episode reveals a structural shift away from indiscriminate adoption of AI tools toward targeted deployment based on business needs within the MSP sector. According to Uptime Global, a channel-only outsourcing provider, premature or hype-driven implementation of AI frequently results in incomplete projects and missed operational gains. The review of AI execution within MSP ticketing environments shows that sustainable value emerges when organizations align AI initiatives with clearly identified business issues, rather than searching for use cases to justify a technology already acquired. Concrete evidence from Uptime Global's experience indicates that approximately 25% of their MSP partners have deployed notable AI solutions beyond ticket triage functions in the past 18 months, according to Jason Kemsley, Chief Revenue Officer. Outcomes vary: roughly half saw ticket volume reductions of 10–25%, while the remainder experienced limited value or customer dissatisfaction tied to inadequate human involvement in support processes. Uptime's operational model uses a confidence threshold for AI-driven actions, where only outputs above 98% confidence automatically execute—mirroring human engineer accuracy rates—and anything below triggers human review. Supporting developments further highlight the shift's operational impact. Uptime Global has eliminated dedicated triage and dispatch roles due to increased AI efficiency, resulting in a role blend where “first responders” now handle both traditional triage and basic technical support tasks within set time limits . The company's pricing structure is affected by AI efficiency, creating margin pressure as contract models based on per-ticket or per-device pricing are exposed to declining ticket volume and shifting customer expectations around service value and outcomes. For MSPs and IT service providers, the operational implications center on increased pricing pressure, the erosion of certain labor-based roles, and the requirement to redesign governance and accountability models to accommodate both automated and human ticket outcomes. Vendor dependency grows as MSPs rely on AI-driven platforms to triage, allocate, and resolve tickets, increasing exposure to platform-specific risks and necessitating clear thresholds for AI confidence and human intervention. Contract structures that do not account for dynamic efficiency gains may create pricing misalignment and customer dissatisfaction over time, emphasizing the need for providers to actively manage and transparently communicate both the tradeoffs and limits of AI-enabled support. Supported by:ProofpointScalePad

In this episode, we kick things off in California, where organized labor is aggressively challenging the state's newly implemented autonomous truck framework. The California Teamsters filed suit in Alameda County Superior Court, arguing that the DMV improperly fast-tracked driverless truck testing regulations through an expedited process reserved for minor updates. Despite the legal challenge, the permit queue continues to move forward with Aurora Innovation and Kodiak AI already holding drivered testing permits. Meanwhile, two powerful trucking industry groups are sounding the alarm over a recent appellate court decision they say could fundamentally upend the entire carrier liability model. The American Trucking Associations and the Truckload Carriers of America filed a joint amicus brief requesting a full en banc hearing to reconsider a Fifth Circuit ruling that found Penske Logistics liable for a fatal crash involving a double-brokered driver the company knew nothing about. The associations warn that if the precedent stands, the entire trucking industry may have been violating federal leasing regulations for decades. Finally, we cover a long-awaited federal transparency rule for freight brokers that has cleared a critical Washington checkpoint. The Federal Motor Carrier Safety Administration sent its broker transparency rulemaking to the White House on August twenty-seventh, marking the first concrete movement since the comment period closed in March twenty twenty-five. The rule would require brokers to maintain transaction records electronically and provide copies to carriers or shippers within forty-eight hours of a request. Follow the FreightWaves NOW Podcast Other FreightWaves Shows Learn more about your ad choices. Visit megaphone.fm/adchoices

Credits: 0.75 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  Episode resource links:  Zhou H et al.  Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355.  eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884  Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041   Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257  Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698.  Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930.  Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.  Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.:  American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022.  Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485.  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234.  Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455  Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666  Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301.  Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015  Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024  Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575  Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1  Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2026 European Society of Cardiology Congress. Hosted by JAMA Executive Editor Gregory Curfman, MD, with JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editors Gregg C. Fonarow, MD, and Paz Tayal, BMBCh, PhD. Related Content: Cardiovascular Magnetic Resonance to Guide Defibrillator Implantation for LVEF of 36% to 50% LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction Pulmonary Vein Isolation Using Pulsed Field Ablation With vs Without Posterior Wall Isolation in Patients With Symptomatic Persistent Atrial Fibrillation Digital Outreach to Improve Statin Refills in Patients With Low Statin Adherence Anticoagulation Monotherapy vs Antiplatelet Monotherapy After Transcatheter Aortic Valve Implant 124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy Low-Voltage Ablation in Persistent Atrial Fibrillation Electrocardiogram-Based Deep Learning to Prioritize Testing for Transthyretin Amyloid Cardiomyopathy Artificial Intelligence–Enabled Acquisition and Interpretation for Screening Aortic Stenosis Machine Learning–Driven Risk Prediction Model in Transthyretin Amyloid Cardiomyopathy Causal Endotype–Based Classification of Myocardial Infarction Prognostic Thresholds of Tricuspid Regurgitation in Transthyretin Amyloid Cardiomyopathy Periprocedural Mortality Risk After Elective Atrial Fibrillation Ablation in Japan Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer

Alasdair Black, our lead pastor, continues the Mission series 

This Day in Legal History: The Murder of Emmett TillOn August 28, 1955, fourteen-year-old Emmett Till was abducted, tortured, and murdered in the Mississippi Delta by two white men, Roy Bryant and J.W. Milam, after Till—a Black teenager visiting from Chicago—was accused of offending a white woman in a grocery store. His killers beat him, shot him, weighted his body, and threw it in the Tallahatchie River. He was a child, and his murder, and what came after, helped ignite the modern civil rights movement.The legal story is one of justice utterly failing, and then, slowly, refusing to disappear. Bryant and Milam were tried the next month in a segregated Mississippi courtroom. The trial lasted five days; the all-white, all-male jury deliberated for barely an hour before acquitting both men, with one juror later saying it wouldn't have taken that long if they hadn't stopped for a soda. Protected by double jeopardy, the two men then sold their confession to a magazine for a few thousand dollars, describing in detail how they'd killed the boy they had just been acquitted of murdering. It was one of the starkest demonstrations imaginable that the machinery of Southern justice was not built to deliver justice to Black victims.The significance of August 28, 1955 reaches across the decades. Emmett's mother, Mamie Till-Mobley, made the searing decision to hold an open-casket funeral and let the world photograph her son. That act of witness galvanized a generation. And there is a haunting piece of calendar symmetry worth honoring: exactly eight years later, on August 28, 1963, Martin Luther King Jr. stood at the Lincoln Memorial and delivered the “I Have a Dream” speech to the March on Washington. The law eventually, partially, caught up—the Civil Rights Act, the Voting Rights Act, and, only in 2022, a federal anti-lynching law that bears Emmett Till's name. It's a reminder that some of the most important developments in American law began not in a courtroom win, but in a courtroom failure so profound that the country could not look away.The brothers Andrew and Tristan Tate were back in a Miami federal courtroom this week, shackled, asking a judge to release them on bond while they fight extradition to the United Kingdom. The two, who have built a massive and controversial online following, have been held in a federal detention center since their July arrest on U.K. rape and sex-trafficking charges. Their lawyers made a pointed argument: if Romania, where the brothers face a separate sex-crimes case, is willing to let them remain free pending those proceedings, then a U.S. court should free them too—especially since, they argue, two of the most recognizable men on the internet can't exactly disappear. Prosecutors pushed back hard, and here the law is decidedly against the Tates. In ordinary criminal cases, release pending trial is the norm. But international extradition is different: there is a strong, long-standing presumption against bail, rooted in the idea that the United States has a treaty obligation to actually produce the person for the requesting country, and that letting an extradition target go free risks a diplomatic and legal failure if they flee. Courts generally require “special circumstances” to grant bail in an extradition case—a demanding standard—and prosecutors noted the brothers have money and have bragged about holding multiple passports. Legal experts quoted in the coverage thought it unlikely they'd win release. The significance is a useful window into a corner of the law most people never see: that fighting extradition is not like fighting ordinary charges, and the presumption of liberty that normally protects defendants is largely flipped when a foreign government is waiting to prosecute.Tate brothers press for release from US jail during extradition fight | ReutersPBS NewsHour · NPRA federal appeals court has cleared a significant hurdle for Bayer's $7.25 billion settlement of tens of thousands of Roundup cancer claims. The Eighth Circuit dismissed a challenge by a group of objecting plaintiffs who were trying to derail the deal—and the fight was about forum, which sounds dry but matters enormously in mass litigation. Bayer structured this as a class-action settlement in Missouri state court, an unusual move: it's using a single state-court proceeding to try to resolve claims nationwide. The objectors argued that a state court has no business fast-tracking a nationwide resolution, and that the whole thing belongs in front of the federal judge already overseeing the consolidated federal Roundup litigation. A federal judge ruled in June that the case could stay in Missouri state court, and now the Eighth Circuit has agreed, dismissing the appeal. Why does the forum matter so much? Because a settlement that binds a nationwide class of people—including people who haven't actively participated—raises real due-process questions about whether a single state court can bind absent claimants across the country, and because plaintiffs and defendants often have strong strategic preferences about which court, and which rules, govern a mega-settlement. This connects to the Bayer story we covered earlier this summer, when the Supreme Court handed the company a big win on failure-to-warn claims; this settlement is the other half of Bayer's campaign to finally contain a decade of Roundup litigation. A hearing to approve the deal is set for September 14, with roughly 65,000 claims hanging in the balance. The significance is that Bayer is close to buying its way out of a liability that has dogged it for years—and the courts just removed one of the last procedural obstacles.US court dismisses appeal over objections to $7.25 billion Roundup deal | ReutersRTÉ · Maryland Daily RecordAnd finally—though this is anything but a footnote—the biggest story of the week, and arguably the summer: Meta has agreed to pay up to $18 billion and fundamentally change how its apps work for teenagers, settling the landmark case accusing it of designing Facebook and Instagram to addict children. This is the resolution of the very trial we watched begin just ten days ago—the 29-state case in Oakland, with the whistleblower testimony from Arturo Bejar. Rather than let it run to a verdict, Meta settled, and the numbers are staggering: more than $17.6 billion to 48 states, D.C., Puerto Rico, and the territories, plus another $459 million to resolve privacy claims tied to the old Cambridge Analytica scandal. But the money may be the less important part. For the next decade, Meta has agreed to concrete design changes: teens will be capped at two hours a day on the apps, and blocked from using them between midnight and 6 a.m. without a parent's consent. And in a clever pressure mechanism, part of the payout is contingent on whether YouTube and TikTok adopt similar protections—effectively using this settlement to try to move the whole industry. Everything we've tracked all summer led here: the New Mexico verdict, the Tennessee trial, the bellwether cases, the Ninth Circuit clearing these suits past Section 230. This is the reckoning arriving. It still needs approval from Judge Yvonne Gonzalez Rogers, who presided over the trial, but if it holds, it's one of the largest consumer-protection settlements in American history—and, more consequentially, the first time a court-supervised deal will reach inside these platforms and re-engineer them for the safety of kids. The era of treating social media's effect on children as an unregulated externality may have just ended, not with a verdict, but with $18 billion and a clock that shuts the app off at midnight.Meta reaches $18 billion of settlements over children's social media addiction | ReutersCNN · Al Jazeera This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Read the full show notes: https://www.draimee.org/from-patient-connection-to-policy-change-advancing-fertility-amp-ivf-care-in-the-u-s-with-guest-kaylen-silverberg-md   In this episode of The Egg Whisperer Show, I'm thrilled to welcome Dr. Kaylen Silverberg, medical director and managing partner at Texas Fertility Center, co-founder of Ovation Fertility, and a leading advocate for patients navigating IVF and reproductive medicine in the United States. Dr. Silverberg shares his journey from aspiring heart surgeon to passionate fertility specialist, and how his deep connections with patients inspired him to bridge the gap between clinical care and national policy change.   Watch this episode on YouTube.   In this episode, we cover:   Dr. Silverberg's personal journey from heart surgery to reproductive medicine The power of patient stories in influencing national policy and lawmakers The mission and current legislative efforts of Americans for IVF Recent changes and proposals to make fertility medications and IVF more affordable The impact of bipartisan advocacy and the importance of building relationships with representatives Advances in endometriosis research and its effect on fertility The promise and limitations of genetic testing in IVF How listeners can get involved in advocacy and make their voices heard   Resources:   Texas Fertility Center: https://www.txfertility.com Americans for IVF: https://americansforivf.org Resolve: The National Infertility Association: https://resolve.org American Society for Reproductive Medicine: https://asrm.org Dr. Silverberg's Instagram: https://www.instagram.com/lets_talk_about_fertility/ Subscribe to The Egg Whisperer Show on YouTube and Spotify Join Dr. Aimee's IVF Class at The Egg Whisperer School Learn About Dr. Aimee's Fertility Essentials

Show SummaryOn today's episode, we're having a conversation with Navy Veteran Dr. Erik Won, President and Chief Medical Officer of Wave Neuroscience, an organization utilizing advanced neuroimaging and magnetic resonance therapy to help veterans recover from post-traumatic stress. DisclaimerThis podcast is for informational and educational purposes only and does not establish a doctor-patient relationship. The views and opinions expressed by the guest are entirely his own and do not reflect the views, policies, or official positions of his employer or company. Content is not intended to substitute for professional medical advice, diagnosis, or treatment.  Wave supplies MeRT to licensed clinics who provide treatment to patients. Talk to your physician to see if MeRT is right for you. Episode Partner:Our sponsor this week is Aetna, a trusted health care company, committed to serving Veterans, military families, and caregivers through meaningful, community-centered care. Provide FeedbackAs a dedicated member of the audience, we would like to hear from you. If you PsychArmor has helped you learn, grow, and support those who've served and those who care for them, we would appreciate hearing your story. Please follow this link to share how PsychArmor has helped you in your service journey Share PsychArmor StoriesAbout Today's GuestDr. Erik Won is President and Chief Medical Officer of Wave Neuroscience, Inc; a biotechnology company that has innovated breakthrough technologies called Magnetic e-Resonance Therapy (MeRT) and Synchronized Transcranial Magnetic Stimulation (sTMS). MeRT recently received FDA Breakthrough Technology designation and FDA clearance for Post-Traumatic Stress Disorders. These approaches utilize computational neuroanalytics and brain imaging to customize treatment protocols with the aim of restoring optimal neurological function.These modalities represent a form of precision-guided medicine that has been researched or is currently being used by premier institutions such as US Special Operations Command, Stanford University School of Medicine, Duke University - Human Performance Opti-Lab, University of Southern California (USC) Center for Neurorestoration, the University of California Los Angeles (UCLA) - David Geffen School of Medicine, University of Pennsylvania, Brown University, Air Force Research Laboratory, and the Texas A&M Institute for Bioscience and Technology.Erik joined Wave Neuroscience after serving as the Chief Physician and Chief Technology Officer (Health Services) for the Boeing Company. He also served as a US Navy Flight Surgeon for Marine Medium Helicopter Squadron 268, and received the distinction of serving as the ACE Flight Surgeon for the 11th Marine Expeditionary Unit, 1st Marine Expeditionary Force. Dr. Won has been published in numerous peer-reviewed journals, textbooks, and presented in numerous academic conferences. He completed his residency at the Harvard OEM combined residency program and was appointed Chief Resident. He received a Masters in Public Health (MPH) from the Harvard School of Public Health and Masters in Business Administrations (MBA) from the University of Southern California, Marshall School of BusinessLinks Mentioned During the EpisodeWave Neuroscience WebsiteBrain Treatment Center WebsitePsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is the PsychArmor course Brain Health & Wellness Learning Series – PTSD. Nearly everyone goes through a traumatic event at least once during their lifetime. Military service members and Veterans are especially vulnerable to the lasting effects of post-traumatic stress due to the nature of their duties and experiences. While this can be a difficult diagnosis to navigate, it is treatable, and social support is one of the leading factors for lasting recovery. Having someone to trust and confide in while feeling heard and validated is a vital part of the healing process. This series on post-traumatic stress disorder explores the presentation and diagnosis of PTSD, its impact on both the Veterans you support and the lives of those around them, and effective treatment modalities, so you'll be better equipped to provide meaningful support. You can find the resource here: https://learn.psycharmor.org/courses/WWP-BHW-PTSD Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on XPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

Interview with Luis Azevedo, Chairman and CEO, Bravo MiningOur previous interview: https://www.cruxinvestor.com/posts/bravo-mining-tsxvbrvo-double-grades-and-resource-up-to-236-million-tons-in-tier-one-pgm-deposit-7934Recording date: 25th August 2026Bravo Mining (TSXV:BRVO, OTCQX:BRVMF) is advancing its 100%-owned Luanga PGM+Au+Ni deposit in Brazil's Carajás Mineral Province through a Pre-Feasibility Study guided for Q3 2026, while simultaneously extending two secondary discoveries — a nickel-copper sulphide system at the Babylon target and an early-stage copper-gold exploration programme — that management believes could add materially to the project's long-term optionality.The immediate news is a set of assay results from drill hole DDH26LU347 at Babylon, adjacent to Luanga's North Sector. The hole intercepted 13.4 metres at 1.55% nickel, 0.33% copper and 2.02 g/t PGM+Au (including a higher-grade 6.7-metre interval at 2.25% nickel and 3.14 g/t PGM+Au), plus a separate 6.0-metre interval grading 6.81 g/t PGM+Au. CEO Luis Azevedo characterises the nickel-copper result as evidence the deposit could ultimately support underground mining grades in addition to its established open-pit resource, with a large Induced Polarisation anomaly at roughly 700 metres depth now queued for follow-up drilling.On the core PGM story, the PFS — pushed one quarter from Q2 to Q3 2026 — is being built around metallurgical testwork showing Jameson Cell flotation technology can lift platinum, palladium and gold recoveries by 5-10% and nickel recoveries by 5-30% against conventional Denver cells, while cutting mass pull by up to 50%. Glencore Technology has independently reviewed the metallurgical database and indicated it is prepared to issue performance guarantees on the assumptions. Azevedo argues the practical effect is a larger, more profitable pit rather than a simple recovery uplift, which is the stated reason the study needed the extra quarter.Bravo held approximately $94 million in cash at the time of interview, which management says funds the PFS, permitting and 2026 drilling without near-term dilution. Beyond the treasury, the company has structured but not yet drawn on two further levers: an indicative $280 million offer for a portion of its gold credit, and an existing $300 million credit line from Orion. A PGM offtake has drawn interest from multiple parties but remains unpriced pending bankable feasibility numbers.On permitting, Bravo already holds its preliminary licence and plans to submit for the Installation Licence within one to two weeks of the PFS release, targeting approval within six months to a year based on the company's track record with Brazilian regulators. A construction decision is targeted roughly six months after the PFS, with construction possible from mid-2028, pending a Q1 2027 resource update and a Q3 2027 Definitive Feasibility Study.The 2025 PEA's vertically-integrated smelter scenario has also become more attractive: rising sulphuric acid byproduct pricing lifts that case's NPV from approximately $1.2 billion to $1.68 billion versus the base concentrate-sale case, though management has not yet decided on timing.Separately, a copper-gold division led by 31-year Vale veteran Fabio Masotti is running IP surveying ahead of an 8,000-metre H2 2026 drill programme — a third, still unpriced source of optionality that management says could eventually support a standalone corporate structure if results warrant it.Learn more: https://cruxinvestor.com/companies/bravo-miningSign up for Crux Investor: https://cruxinvestor.com/subscribe

In the world's shortest ever transfer "saga" Crystal Palace have rebuffed Liverpool's late transfer window advances for Ismaïla Sarr. Pajak reacts! Hosted on Acast. See acast.com/privacy for more information.

Featuring perspectives from Dr Matthew Matasar and Dr Sonali M Smith, including the following topics: Introduction: Lymphoma Survivorship (0:00) Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Dr Matasar (6:49) Novel Treatment Approaches for Follicular Lymphoma and Mantle Cell Lymphoma — Dr Smith (32:14) CME information and select publications

Interview with Meredith Eades, President and CEO, EraNova Metals  Our previous interview: https://www.cruxinvestor.com/posts/eranova-metals-dual-path-critical-minerals-play-with-30-million-infrastructure-advantage-in-canada-9037Recording date: 24th August 2026EraNova Metals has released the first independent economic study on its Adanac Molybdenum Project since 2008, and the numbers give investors a concrete basis for evaluating a story that has, until now, rested largely on historical potential. The Preliminary Economic Assessment (PEA), prepared by Tetra Tech Canada, values Adanac at a C$714.4 million after-tax NPV with a 23.5% IRR and a 2.6-year payback, using a US$25.00 per pound long-term molybdenum price. At the current spot price of US$31.91 per pound, President and CEO Meredith Eades said the after-tax NPV rises to C$1.29 billion, with IRR climbing to 30.2%.What separates Adanac from many junior molybdenum stories is the amount of work already completed. The project was drilled more than 73,000 metres, advanced through a full feasibility study, and received an Environmental Assessment Certificate in 2007, before the 2008 financial crisis halted construction. EraNova estimates the value of this historical infrastructure at more than C$100 million - road access, site works and engineering that a typical greenfield developer would need years and substantial capital to replicate. Combined with a mineral resource that is 93% Measured and Indicated, the technical foundation for a Feasibility Study is already largely in place, reducing the need for extensive further drilling.The macro backdrop adds to the case. Around 90% of the world's molybdenum supply arrives as a by-product of copper mining, and as copper operations increasingly move underground, by-product molybdenum grades and volumes are under pressure. That leaves relatively few primary molybdenum developers positioned to meet growing demand from high-strength steel applications in pipelines, energy infrastructure, aerospace and defence.Eades is explicit that EraNova is not attempting to raise its full C$953.3 million initial capital requirement in one step. Instead, the company is using the PEA as a credibility milestone to open conversations with government funding programmes, strategic partners and potential off-takers, including molybdenum consumers such as Freeport, Centerra and Molymet. A roughly 3,000-metre engineering support drilling programme is planned to advance toward Feasibility, alongside an updated environmental assessment process conducted in continued engagement with the Taku River Tlingit First Nation.Against a market capitalisation the company puts at approximately $10 million, the PEA's economics represent a significant disconnect from the underlying asset value - if the numbers hold through Feasibility. Risks remain: the project still requires a full Feasibility Study, updated permits, and a near-billion-dollar capital build, all of which carry execution and dilution risk as capital is raised in stages. For investors willing to accept pre-production development risk, EraNova offers a rare primary molybdenum exposure with an unusually advanced permitting and engineering head start, plus exploration optionality across the wider Ruby Creek property - including high-grade silver, gold and tungsten targets - that could deliver catalysts independent of the molybdenum development timeline.Learn more: https://www.cruxinvestor.com/companies/eranova-metalsSign up for Crux Investor: https://cruxinvestor.com

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Novel Treatment Approaches for Non-Hodgkin Lymphoma | Faculty Presentation 2: Novel Treatment Approaches for Follicular Lymphoma and Mantle Cell Lymphoma — Sonali M Smith, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Novel Treatment Approaches for Non-Hodgkin Lymphoma | Faculty Presentation 1:  Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Matthew Matasar, MD CME information and select publications

Stay informed on current events, visit www.NaturalNews.com  - The Depopulation Theory (0:10) - Advances in AI Video Rendering (6:25) - Soggy Peaches Music Video (17:30) - Nuclear War Risks and Survival (27:18) - Unjected Community and Mission (49:19) - Genetic Integrity and mRNA Risks (102:06) - The Spiritual Battle for Humanity (104:11) Watch more independent videos at http://www.brighteon.com/channel/hrreport  ▶️ Support our mission by shopping at the Health Ranger Store - https://www.healthrangerstore.com ▶️ Check out exclusive deals and special offers at https://rangerdeals.com ▶️ Sign up for our newsletter to stay informed: https://www.naturalnews.com/Readerregistration.html Watch more exclusive videos here: